PharmCube presents the most groundbreaking translational medicine targets of 2024, showcasing innovations—from novel immune checkpoints to cutting-edge gene therapies—that are reshaping drug discovery across oncology, immunology and rare diseases. This year's report features 25 targets, including new discoveries, clinical proof-of-concept validations and emerging technologies. With growing contributions from Chinese researchers, this report underscores the global impact of translational medicine in addressing unmet medical needs while offering actionable insights for investments, partnerships and staying ahead in pharmaceutical R&D.